Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma.

Although plasma biomarkers are considered the most suitable candidates for evaluating sorafenib efficacy, only a limited number of trials, such as the SHARP trial, have produced results with borderline significance.

also in 7,017 other papers

However, among all HCC cases, the proportion of HBV- and HCV-related cases is declining, while there is an increasing trend in HCC cases caused by metabolic dysfunction-associated fatty liver disease (MAFLD).

also in 63,971 other papers